These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30498418)

  • 21. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
    Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
    Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sentinel lymph node biopsy after previous axillary surgery: A review.
    Kothari MS; Rusby JE; Agusti AA; MacNeill FA
    Eur J Surg Oncol; 2012 Jan; 38(1):8-15. PubMed ID: 22032909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refining the Performance of Sentinel Lymph Node Biopsy Post-neoadjuvant Chemotherapy in Patients with Pathologically Proven Pre-treatment Node-positive Breast Cancer: An Update for Clinical Practice.
    El Hage Chehade H; Headon H; Kasem A; Mokbel K
    Anticancer Res; 2016 Apr; 36(4):1461-71. PubMed ID: 27069121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is it always necessary to perform an axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer?
    Osorio-Silla I; Gómez Valdazo A; Sánchez Méndez JI; York E; Díaz-Almirón M; Gómez Ramírez J; Rivas Fidalgo S; Oliver JM; Álvarez CM; Hardisson D; Díaz Miguel M; Lobo F; Díaz Domínguez J
    Ann R Coll Surg Engl; 2019 Mar; 101(3):186-192. PubMed ID: 30421628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA Analysis.
    Kolberg HC; Kühn T; Krajewska M; Bauerfeind I; Fehm TN; Fleige B; Helms G; Lebeau A; Stäbler A; Schmatloch S; Hausschild M; Schwentner L; Schrenk P; Loibl S; Untch M; Kolberg-Liedtke C
    Geburtshilfe Frauenheilkd; 2020 Dec; 80(12):1229-1236. PubMed ID: 33293731
    [No Abstract]   [Full Text] [Related]  

  • 26. [Normalization in axillary lymph node management after neoadjuvant therapy for breast cancer].
    Wu D; Liu SY; Amina M; Fan ZM
    Zhonghua Wai Ke Za Zhi; 2019 Feb; 57(2):97-101. PubMed ID: 30704211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
    Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
    Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.
    Wong SM; Weiss A; Mittendorf EA; King TA; Golshan M
    Ann Surg Oncol; 2019 Oct; 26(11):3517-3525. PubMed ID: 31342389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical utility of combining pre-operative axillary ultrasonography and fine needle aspiration cytology with radionuclide guided sentinel lymph node biopsy in breast cancer patients with palpable axillary lymph nodes.
    Usmani S; Ahmed N; Al Saleh N; abu Huda F; Amanguno HG; Amir T; al Kandari F
    Eur J Radiol; 2015 Dec; 84(12):2515-20. PubMed ID: 26474908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sentinel lymph node biopsy alone after neoadjuvant chemotherapy in patients with initial cytology-proven axillary node metastasis.
    Kim JY; Kim MK; Lee JE; Jung Y; Bae SY; Lee SK; Kil WH; Kim SW; Kim KS; Nam SJ; Han S
    J Breast Cancer; 2015 Mar; 18(1):22-8. PubMed ID: 25834607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update.
    Friedrich M; Kühn T; Janni W; Müller V; Banys-Pachulowski M; Kolberg-Liedtke C; Jackisch C; Krug D; Albert US; Bauerfeind I; Blohmer J; Budach W; Dall P; Fallenberg EM; Fasching PA; Fehm T; Gerber B; Gluz O; Hanf V; Harbeck N; Heil J; Huober J; Kreipe HH; Kümmel S; Loibl S; Lüftner D; Lux MP; Maass N; Möbus V; Mundhenke C; Nitz U; Park-Simon TW; Reimer T; Rhiem K; Rody A; Schmidt M; Schneeweiss A; Schütz F; Sinn HP; Solbach C; Solomayer EF; Stickeler E; Thomssen C; Untch M; Witzel I; Wöckel A; Thill M; Ditsch N
    Geburtshilfe Frauenheilkd; 2021 Oct; 81(10):1112-1120. PubMed ID: 34629490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update.
    Schwartz GF
    Breast J; 2004; 10(2):85-8. PubMed ID: 15009032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.
    Li J; Jia S; Zhang W; Qiu F; Zhang Y; Gu X; Xue J
    BMC Surg; 2015 Jun; 15():79. PubMed ID: 26123412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.
    Simons JM; van Nijnatten TJA; van der Pol CC; Luiten EJT; Koppert LB; Smidt ML
    Ann Surg; 2019 Mar; 269(3):432-442. PubMed ID: 30312200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer.
    Takei H; Suemasu K; Kurosumi M; Horii Y; Yoshida T; Ninomiya J; Yoshida M; Hagiwara Y; Kamimura M; Hayashi Y; Inoue K; Tabei T
    Breast Cancer; 2007; 14(1):16-24. PubMed ID: 17244989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
    Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
    Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Axillary and internal mammary sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy.
    Cao XS; Li HJ; Cong BB; Sun X; Qiu PF; Liu YB; Wang CJ; Wang YS
    Oncotarget; 2016 Nov; 7(45):74074-74081. PubMed ID: 27738336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Axillary surgery in breast cancer: the beginning of the end.
    Dumitru D; Khan A; Catanuto G; Rocco N; Nava MB; Benson JR
    Minerva Chir; 2018 Jun; 73(3):314-321. PubMed ID: 29589679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer.
    Palesty JA; Foster JM; Hurd TC; Watroba N; Rezaishiraz H; Edge SB
    J Surg Oncol; 2006 Feb; 93(2):129-32. PubMed ID: 16425295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.